Smaller, cheaper, faster: where next for liquid biopsies?

Area of Science:

• Oncology
• Molecular Diagnostics
• Genomics

Background:

• Liquid biopsy (LB) provides a minimally invasive method for cancer diagnosis and monitoring.
• Next-generation sequencing (NGS) enhances LB accuracy and clinical validity.
• Tissue biopsy (TB) remains the gold standard but is limited by sample inadequacy.

Purpose of the Study:

• To evaluate LB as a complementary approach to TB for molecular profiling.
• To assess the cost-effectiveness of LB in clinical settings.
• To explore the potential of advanced platforms to improve LB efficiency and scalability.

Main Methods:

• Review of current literature on LB and TB.
• Analysis of cost-effectiveness data for LB implementation.
• Discussion of emerging technologies for LB analysis.

Main Results:

• LB effectively addresses limitations of TB, providing accessible nucleic acid sources.
• Cost-effectiveness analyses indicate optimized healthcare spending with appropriate LB application.
• Advanced liquid handling platforms promise improved LB efficiency, reduced costs, and higher throughput.

Conclusions:

• LB is a valuable tool in cancer care, complementing TB and improving molecular profiling.
• Strategic implementation of LB can enhance healthcare economics and patient quality-adjusted life years.
• Technological advancements in LB platforms are crucial for its broader clinical adoption and impact.